KV Pharmaceuticals Settles Derivative Suit

Law360, New York (April 9, 2008, 12:00 AM EDT) -- KV Pharmaceuticals Inc. will soon put its stock options backdating litigation behind it, after reaching a settlement with shareholders who brought a derivative suit against the company's directors.

St. Louis-based KV said Monday that it had reached a settlement in the derivative suit filed over the company's stock options granting practices. The company did not disclose the amount of the settlement, but said it expected insurance to cover the fees and costs associated with the case.

“Upon its finalization, the settlement of this litigation will be...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.